Document is current

Article History

Received: 27 March 2024

Accepted: 3 January 2025

First Online: 20 January 2025

Declarations

:

: All procedures were performed in accordance with the Helsinki Declaration. The breast cancer biospecimens used for research consisted of leftover material from samples collected during standard surgical and medical approaches at INT. Samples were donated by patients to the Institutional BioBank for research purposes, and aliquots were allocated to this study after approval by the Institutional Review Board and a specific request to the Independent Ethics Committee of the INT (N. INT 170–20; Responsible Researcher Dr G. Pruneri).Animal experiments were approved by the Ethics Committee for Animal Experimentation of the INT according to institutional guidelines and the Italian Law (D-lgs 26/2014). In vivo experiments were approved by the Italian Ministry of Health (authorization numbers 1091/2020-PR and 74312.31.EXT.9; Resposible Researcher Dr S.M. Pupa).

: Not applicable.

: F. Pietrantonio reports honoraria/consulting fees from Amgen, Merck-Serono, Sanofi, Ely Lilly, Bayer, Servier, Pierre-Fabre, AstraZeneca, BMS, MSD, and Organon and research grants from AstraZeneca, BMS, and Incyte. G. Pruneri reports honoraria from Eli Lilly, Roche Foundation One, Bayer, and Novartis. C. Vernieri reports research grants from Roche (to the Institution); honoraria as a speaker for educational events from Eli Lilly, Novartis, Accademia di Medicina, Fenix, and Istituto Gentili and for Advisory Board duties from Eli Lilly, Novartis, Menarini, Pfizer, and Daiichi Sankyo; and consulting fees from Eli Lilly. A. Vingiani reports honoraria from Roche.No disclosures were reported by the other authors.